Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like Receptor Antagonists Normalize Expression of

  Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like
  Receptor Antagonists Normalize Expression of Inflammatory Genes in Psoriasis

--Phase 2 Data of IMO-3100 in Psoriasis to be Presented at IID Meeting 2013--

AAD 71st Annual Meeting

Business Wire

CAMBRIDGE, Mass. -- March 2, 2013

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of
new data showing that its selective Toll-like receptor antagonists, IMO-3100
and IMO-8400, normalized the gene expression of important cytokines in a
preclinical study of skin inflammation that is commonly used as a model of
psoriasis. Notably, genes related to the production of key mediators of
psoriasis including Interleukin (IL) -17, IL-6, IL-12/23, IL-1, IL-21
Receptor, and INF-gamma were restored toward normal levels. The data were
presented by James G. Krueger, M.D., Ph.D, of The Rockefeller University, at
the Late-Breaking Research Symposium on March 2^nd, 2013, during the American
Academy of Dermatology Annual Meeting.

“Our studies show that treatment with IMO-3100 and IMO-8400 reduces
disease-associated expression of the IL-17 and IL-23 inflammatory cascade in
the mouse IL-23-induced skin inflammation model,” said Dr. James Krueger.
“Genes that play a mediating role in psoriasis were returned toward normal
levels with both compounds; and the inclusion of TLR8 activity with IMO-8400
was additive to the effect on gene expression that we observed with the TLR7
and TLR9 antagonist compound. We are now extending this work, with the
analysis of gene expression patterns in skin biopsies from patients treated
with a TLR antagonist in a Phase 2 clinical trial.”

“The data presented by Dr. Krueger provide scientific support for the top-line
results from the proof of concept Phase 2 trial of IMO-3100 in patients with
psoriasis that Idera announced late last year. We look forward to presenting
detailed results from the clinical trial at the International Investigative
Dermatology Annual Meeting in May 2013,” commented Robert Arbeit, M.D., VP of
Clinical Development at Idera. “In addition, during the first quarter, we
completed the single dose portion of a Phase 1 clinical trial of IMO-8400 in
healthy subjects. IMO-8400 was well-tolerated and demonstrated target
engagement of TLRs 7, 8 and 9. The multiple-dose portion of the IMO-8400 Phase
1 trial is ongoing, and we anticipate data during the second quarter of 2013.”

A copy of the presentation is available on the AAD website.

About TLRs and Idera's Autoimmune and Inflammatory Diseases Program

Toll-like receptors (TLRs) play a key role in inflammation and immunity. Of
the 10 human TLRs identified to date, Idera is developing compounds targeted
to TLRs 3, 7, 8 and 9, which are expressed in different cells and serve unique
functions. Using its chemistry-based approach, Idera has created novel drug
candidates that modulate immune responses through either activation or
inhibition of specific TLRs. Inhibition of specific TLRs may be useful in
treating autoimmune disorders, such as systemic lupus erythematosus (SLE),
psoriasis and rheumatoid arthritis, by blocking the induction of multiple
cytokines and signaling pathways. Idera's clinical candidates for application
in autoimmune diseases are IMO-3100, an antagonist of TLR7 and TLR9, and
IMO-8400, an antagonist of TLRs 7, 8 and 9.

A characteristic of autoimmune diseases such as SLE and psoriasis is the
production of autoantibodies, damage-associated molecular patterns, or DAMPs,
and pathogen associated molecular patterns, or PAMPs, that may contain host
nucleic acids. These stimuli activate TLRs 7, 8 and 9 and induce multiple
cytokines and signaling cascades that cause further damage to the body's own
tissues and organs, thereby releasing more self-nucleic acids. Thus, a
pathologic amplification cycle is established, promoting disease maintenance
and progression. In preclinical models of several autoimmune diseases,
IMO-3100 and IMO-8400 inhibited TLR-mediated induction of Th1, Th17 and
inflammasome pathways, leading to the suppression of multiple cytokines
including tumor necrosis factor-alpha, or TNF-α, and interleukins IL-12, IL-6,
IL-17 and IL-1β and improvements in multiple measures of disease. Current
treatments for autoimmune and inflammatory diseases include the use of
monoclonal antibodies to block the activity of one specific cytokine. TLR
antagonists are designed to inhibit induction of immune responses to
autoimmune disease stimuli rather than to block the activity of any one
specific cytokine.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug
discovery platform to create immunomodulatory drug candidates and has a
clinical development program in autoimmune diseases. Additionally, Idera has a
collaboration with Merck & Co. for the use of TLR-targeted candidates as
vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. The
Company is also exploring its gene-silencing oligonucleotide (GSO) technology
for the purpose of inhibiting the expression of disease-promoting genes. For
more information, visit

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For
this purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking statements. There
are a number of important factors that could cause Idera's actual results to
differ materially from those indicated by such forward-looking statements,
including whether Idera’s cash resources will be sufficient to fund the
Company’s continuing operations and the further development of the Company’s
autoimmune disease program; whether results obtained in preclinical studies
and early clinical trials will be indicative of results obtained in future
clinical trials; whether products based on Idera's technology will advance
into or through the clinical trial process on a timely basis or at all and
receive approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's products
receive approval, they will be successfully distributed and marketed; whether
the Company will be able to license any of its TLR target candidates on a
timely basis or at all; whether the Company's collaboration with Merck & Co,
Inc., will be successful; whether the patents and patent applications owned or
licensed by the Company will protect the Company's technology and prevent
others from infringing it; and such other important factors as are set forth
under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2012 which important factors are incorporated
herein by reference. Idera disclaims any intention or obligation to update any
forward-looking statements.


Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
Press spacebar to pause and continue. Press esc to stop.